TidalSense is an AI-powered respiratory diagnostics company headquartered in Cambridge, UK, led by CEO Dr Ameera Patel. Its software device, N-Tidal Diagnose used in combination with N-Tidal hardware, uses AI-analysed tidal breathing — rather than the forced exhalation required by spirometry — to deliver a fast, non-invasive diagnosis of COPD in under five minutes, without specialist training or hospital-grade equipment. N-Tidal Diagnose is the first non-spirometry AI diagnostic device to receive a CE mark under EU MDR (class IIa) for COPD, and has been commissioned and used across multiple healthcare settings.
TidalSense
- Health
- Cambridge, United Kingdom
- £14m
- tidalsense.com
- Update Information
More venture news
- 3 Sept 2026

StrolllStrolll secures £4.3m in funding from Innovate UK and IW Capital for augmented reality neurorehabilitation
EquityHealth - 1 Sept 2026

HealfHealf secures funding led by SEMCAP Beauty & Wellness to expand its personalised wellbeing platform
EquityHealth - 11 Mar 2025

StrolllStrolll raises £10m Series A led by IW Capital to expand AR-based neurorehabilitation
Series AHealth
